[Cytoreductive effect of recombinant alfa-interferon in patients with myelofibrosis with myeloid metaplasia].
Barosi
G
G
Dipartimento di Medicina Interna e Terapia Medica, Sezione Clinica Medica 2, IRCCS Policlinico S. Matteo, Pavia.
Liberato
N L
NL
Costa
A
A
Ascari
E
E
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000097:blood / Q000628:therapy*; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Effetto citoriduttivo dell'alfa-interferon ricombinante in pazienti con mielofibrosi con metaplasia mieloide.